These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 22809551

  • 21. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC, Troutt JS, van Greevenbroek MM, Ferreira I, Feskens EJ, van der Kallen CJ, Schaper NC, Schalkwijk CG, Konrad RJ, Stehouwer CD.
    Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
    [Abstract] [Full Text] [Related]

  • 22. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?
    Chan DC, Lambert G, Barrett PH, Rye KA, Ooi EM, Watts GF.
    Clin Chem; 2009 Nov; 55(11):2049-52. PubMed ID: 19713274
    [Abstract] [Full Text] [Related]

  • 23. Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ε2.
    Brouwers MC, van Greevenbroek MM, Konrad RJ, Troutt JS, Schaper NC, Stehouwer CD.
    Clin Sci (Lond); 2014 May; 126(9):679-84. PubMed ID: 24308640
    [Abstract] [Full Text] [Related]

  • 24. PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program.
    Arsenault BJ, Pelletier-Beaumont E, Alméras N, Tremblay A, Poirier P, Bergeron J, Després JP.
    Atherosclerosis; 2014 Oct; 236(2):321-6. PubMed ID: 25128757
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9.
    Melone M, Wilsie L, Palyha O, Strack A, Rashid S.
    J Am Coll Cardiol; 2012 May 08; 59(19):1697-705. PubMed ID: 22554600
    [Abstract] [Full Text] [Related]

  • 28. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
    Zhang Y, Xu RX, Li S, Zhu CG, Guo YL, Sun J, Li JJ.
    Nutr Metab Cardiovasc Dis; 2015 Apr 08; 25(4):426-33. PubMed ID: 25770756
    [Abstract] [Full Text] [Related]

  • 29. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K, Park BS, Kim YW, Vaziri ND.
    Am J Kidney Dis; 2014 Apr 08; 63(4):584-9. PubMed ID: 24315769
    [Abstract] [Full Text] [Related]

  • 30. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.
    Leander K, Mälarstig A, Van't Hooft FM, Hyde C, Hellénius ML, Troutt JS, Konrad RJ, Öhrvik J, Hamsten A, de Faire U.
    Circulation; 2016 Mar 29; 133(13):1230-9. PubMed ID: 26896437
    [Abstract] [Full Text] [Related]

  • 31. Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins.
    Kwakernaak AJ, Lambert G, Dullaart RP.
    Clin Biochem; 2014 May 29; 47(7-8):679-82. PubMed ID: 24680982
    [Abstract] [Full Text] [Related]

  • 32. Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease.
    Li S, Zhang Y, Xu RX, Guo YL, Zhu CG, Wu NQ, Qing P, Liu G, Dong Q, Li JJ.
    Ann Med; 2015 May 29; 47(5):386-93. PubMed ID: 26153823
    [Abstract] [Full Text] [Related]

  • 33. The effect of insulin on circulating PCSK9 in postmenopausal obese women.
    Awan Z, Dubuc G, Faraj M, Dufour R, Seidah NG, Davignon J, Rabasa-Lhoret R, Baass A.
    Clin Biochem; 2014 Aug 29; 47(12):1033-9. PubMed ID: 24721682
    [Abstract] [Full Text] [Related]

  • 34. Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels.
    Chernogubova E, Strawbridge R, Mahdessian H, Mälarstig A, Krapivner S, Gigante B, Hellénius ML, de Faire U, Franco-Cereceda A, Syvänen AC, Troutt JS, Konrad RJ, Eriksson P, Hamsten A, van 't Hooft FM.
    Arterioscler Thromb Vasc Biol; 2012 Jun 29; 32(6):1526-34. PubMed ID: 22460556
    [Abstract] [Full Text] [Related]

  • 35. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
    Nozue T, Hattori H, Ishihara M, Iwasaki T, Hirano T, Kawashiri MA, Yamagishi M, Michishita I.
    Am J Cardiol; 2013 May 15; 111(10):1415-9. PubMed ID: 23433768
    [Abstract] [Full Text] [Related]

  • 36. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease.
    Zhang Y, Zhu CG, Xu RX, Li S, Guo YL, Sun J, Li JJ.
    J Clin Lipidol; 2014 May 15; 8(5):494-500. PubMed ID: 25234562
    [Abstract] [Full Text] [Related]

  • 37. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A.
    Hepatology; 2008 Aug 15; 48(2):646-54. PubMed ID: 18666258
    [Abstract] [Full Text] [Related]

  • 38. The effects of estrogen on serum level and hepatocyte expression of PCSK9.
    Guo W, Fu J, Chen X, Gao B, Fu Z, Fan H, Cui Q, Zhu X, Zhao Y, Yang T, Fan D, Zhou H.
    Metabolism; 2015 Apr 15; 64(4):554-60. PubMed ID: 25665485
    [Abstract] [Full Text] [Related]

  • 39. Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer.
    Ozkan C, Akturk M, Altinova AE, Cerit ET, Gulbahar O, Yalcin MM, Cakir N, Balos Toruner F.
    Endocr J; 2015 Apr 15; 62(12):1091-9. PubMed ID: 26490048
    [Abstract] [Full Text] [Related]

  • 40. Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9: The Role of STAT3.
    Macchi C, Greco MF, Botta M, Sperandeo P, Dongiovanni P, Valenti L, Cicero AFG, Borghi C, Lupo MG, Romeo S, Corsini A, Magni P, Ferri N, Ruscica M.
    Am J Pathol; 2020 Nov 15; 190(11):2226-2236. PubMed ID: 32798443
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.